Loading clinical trials...
Loading clinical trials...
Phase II, Randomized, Open-label, Multicenter Study in Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Who Have PRIMary Resistance to Abiraterone Acetate or Enzalutamide Treatment Comparing the Anti-tumor Effect of CABazitaxel to Alternative Androgen Receptors (AR) Targeted Therapy
Conditions
Interventions
Cabazitaxel XRP6258
Ezalutamide
+2 more
Locations
24
United States
Investigational Site Number 840030
Muscle Shoals, Alabama, United States
Investigational Site Number 840024
Anchorage, Alaska, United States
Investigational Site Number 840028
Anaheim, California, United States
Investigational Site Number 840004
Sacramento, California, United States
Investigational Site Number 840002
Boca Raton, Florida, United States
Investigational Site Number 840027
Lakeland, Florida, United States
Start Date
June 17, 2015
Primary Completion Date
May 10, 2018
Completion Date
May 10, 2018
Last Updated
June 21, 2019
NCT07004582
NCT06849544
NCT07115914
NCT05327465
NCT06165302
NCT07118436
Lead Sponsor
Sanofi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions